{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:51:31Z","timestamp":1793836291427,"version":"4.6.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.amjcard.2019.10.028","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T19:01:56Z","timestamp":1573758116000},"page":"S36-S44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"S1","title":["Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits"],"prefix":"10.1016","volume":"124","author":[{"given":"Subodh","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.10.028_bb0005","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0010","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1001\/jama.2014.4115","article-title":"Management of comorbid diabetes mellitus and worsening heart failure","volume":"311","author":"Khan","year":"2014","journal-title":"JAMA."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005539","article-title":"Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure","volume":"6","author":"Swoboda","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0020","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.2337\/dc19-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from theCANVAS Program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0035","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0040","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1007\/s00125-018-4644-9","article-title":"Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME\u00ae randomised trial","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0045","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.jacc.2019.03.002","article-title":"Influence of microvascular disease on cardiovascular events in type 2 diabetes","volume":"73","author":"Verma","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0050","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0055","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus","volume":"138","author":"Radholm","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0060","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1161\/CIRCULATIONAHA.119.040514","article-title":"The serendipitous story of SGLT2 inhibitors in heart failure","volume":"139","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.10.028_bb0065","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes and prior myocardial infarction: a sub-analysis from DECLARE TIMI-58 trial","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1548","article-title":"The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0075","series-title":"DAPA-HF top-line results: dapagliflozin hits primary outcome","author":"Medscape","year":"2019"},{"key":"10.1016\/j.amjcard.2019.10.028_bb0080","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ejhf.1419","article-title":"Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline","volume":"21","author":"Januzzi","year":"2019","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0085","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/eurheartj\/ehx511","article-title":"Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME\u00ae trial","volume":"39","author":"Fitchett","year":"2018","journal-title":"Eur Heart J."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0090","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/CIRCULATIONAHA.118.038339","article-title":"Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality","volume":"139","author":"Savarese","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(18)32824-1","article-title":"Pump, pipes, and filter: do SGLT2 inhibitors cover it all?","volume":"393","author":"Verma","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0105","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0110","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.amjcard.2019.10.026","article-title":"Preventing and treating heart failure with sodium-glucose cotransporter 2 inhibitors","volume":"124","author":"Vaduganathan","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2019.10.028_bb0115","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0120","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0125","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0130","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0135","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamacardio.2017.1891","article-title":"The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure","volume":"2","author":"Verma","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0140","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lfs.2018.01.032","article-title":"The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels","volume":"197","author":"Li","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0150","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0155","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.117.029529","article-title":"Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus","volume":"136","author":"Striepe","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0160","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007046","article-title":"Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects","volume":"7","author":"Wilcox","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0165","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0170","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12933-017-0654-z","article-title":"SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial","volume":"17","author":"Karg","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0180","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0185","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fendo.2018.00421","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity","volume":"9","author":"Wan","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0190","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J Cardiol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0195","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jdiacomp.2019.04.006","article-title":"Tissue sodium content in patients with type 2 diabetes mellitus","volume":"33","author":"Kannenkeril","year":"2019","journal-title":"J Diabetes Complications."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0200","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1681\/ASN.2016060662","article-title":"Skin sodium concentration correlates with left ventricular hypertrophy in CKD","volume":"28","author":"Schneider","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0205","first-page":"575","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie","year":"2018","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0210","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0215","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1712231","article-title":"Relationship between clinic and ambulatory blood-pressure measurements and mortality","volume":"378","author":"Banegas","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0220","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005686","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis","volume":"6","author":"Baker","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0225","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/dc18-2207","article-title":"Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide","volume":"42","author":"Georgianos","year":"2019","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0230","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1161\/CIRCULATIONAHA.118.036568","article-title":"Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension","volume":"139","author":"Ferdinand","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0235","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study","volume":"139","author":"Kario","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12933-017-0510-1","article-title":"A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation","volume":"16","author":"Ott","year":"2017","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0245","doi-asserted-by":"crossref","unstructured":"Kang S, Verma S, Teng G, et al. Empagliflozin attenuates extracellular matrix remodeling by human cardiac fibroblasts: novel translational clues to EMPA-REG OUTCOME. American Heart Association Scientific Sessions: Anaheim, CA; 2017. Abstract 15925.","DOI":"10.1016\/j.cjca.2017.07.330"},{"key":"10.1016\/j.amjcard.2019.10.028_bb0250","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","article-title":"Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC Basic Transl Sci."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0255","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacbts.2018.11.010","article-title":"Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction","volume":"4","author":"Connelly","year":"2019","journal-title":"JACC Basic Transl Sci."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0260","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats","volume":"18","author":"Lee","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0265","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0270","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ajh\/hpz016","article-title":"Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload","volume":"32","author":"Shi","year":"2019","journal-title":"Am J Hypertens."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0275","doi-asserted-by":"crossref","unstructured":"Singh J, Mordi I, Mohan M, et al. Research into the effect of sodium-glucose linked transporter 2 inhibition on left ventricular remodeling in patients with heart failure and diabetes mellitus. American Diabetes Association 78th Annual Scientific Sessions: Orlando, FL; 2018. 256-OR.","DOI":"10.2337\/db18-256-OR"},{"key":"10.1016\/j.amjcard.2019.10.028_bb0280","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0285","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","author":"Verma","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0290","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.117.029166","article-title":"Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease","volume":"136","author":"Kappel","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0295","series-title":"Empagliflozin induces a myocardial metabolic shift from glucose consumption to ketone metabolism that mitigates adverse cardiac remodeling and improves myocardial contractility. American College of Cardiology 67th Annual Scientific Session","first-page":"1318M","author":"Santos-Gallego","year":"2018"},{"key":"10.1016\/j.amjcard.2019.10.028_bb0300","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","article-title":"The failing heart relies on ketone bodies as a fuel","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0305","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0310","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0315","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0320","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0325","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/dom.13229","article-title":"Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis","volume":"20","author":"Packer","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0330","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0335","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0340","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0345","series-title":"The association between uric acid levels and cardiorenal outcomes and death in patients with type 2 diabetes: a sub-analysis of EMPA-REG OUTCOME. American College of Cardiology 68th Annual Scientific Session","first-page":"1134","author":"Verma","year":"2019"},{"key":"10.1016\/j.amjcard.2019.10.028_bb0350","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S2213-8587(16)30196-6","article-title":"Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis","volume":"4","author":"Willeit","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0355","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","article-title":"Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes","volume":"70","author":"Januzzi","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0360","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","article-title":"SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart","volume":"4","author":"Lim","year":"2019","journal-title":"JACC Basic Transl Sci."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0365","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/CIRCRESAHA.112.276915","article-title":"Ca2+\/Calmodulin-dependent protein kinase II \u03b4 mediates myocardial ischemia\/reperfusion injury through nuclear factor-\u03baB","volume":"112","author":"Ling","year":"2013","journal-title":"Circ Res."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0370","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0375","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/EJE-17-0832","article-title":"Mechanisms in endocrinology: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?","volume":"178","author":"Esterline","year":"2018","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0380","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.028_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.08.015","article-title":"A novel effect of SGLT2 inhibition to increase circulating pro-vascular progenitor cells in patients with type 2 diabetes","author":"Hess","year":"2019","journal-title":"Cell Metab"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919311786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919311786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:31:19Z","timestamp":1757572279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919311786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":77,"alternative-id":["S0002914919311786"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.028","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}